MarginsXMarginsX
Home › Markets › Health Care › DBVT

DBV Technologies S.A. (DBVT)

DBVT trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$10.27
-6.76% on the day
Market cap
$645.8M
Small cap
Revenue · 2025
$5.6M
+35.8% on 2024
Net income · 2025
-$146.9M
-2607.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1613780/000162828026021504/0001628280-26-021504-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerDBVT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryFrance
IPO year2014
SEC CIK0001613780
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inFrance

Financials · 2025

LineValue
Revenue$5.6M
Net income-$146.9M
Operating income-$147.1M
Net margin-2607.3%
Operating margin-2609.2%
Revenue growth+35.8%
Cash$194.2M
Total assets$233.7M
P/E (computed)Net income was not positive
P/S (computed)114.6×

Warning signs

Cash runway
10.6 months
$165.7M cash at September 30, 2026
Share count, 1 year
+85.9%
2025-10-27 to 2026-10-26 · +553.0% over 3 years
Going-concern doubt
Yes
10-Q filed October 28, 2026
Insider net buying, 12 months
-$15.5M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, substantial doubt exists about the Company's ability to continue as a going concern within twelve months after the date these condensed consolidated financial statements are issued."
10-Q 2026-10-28
Cash and burn$165.7M cash; operating cash flow -$47.1M a quarter.Report 2026-09-30
Shares outstanding62,877,761 (2026-10-26); 33,822,724 a year earlier; 19,257,711 three years earlier. 3y figure adjusted for split (1-for-2 overall).Cover page 2026-10-26
Reverse splits, 3 years1; latest 1-for-2 on 2024-06-07Source 2024-06-07
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-07-27
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Associés, Paris-La Défense, FrancePCAOB Form AP 2026-04-29
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $15.5M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$1.6M-$64.5M-$51.5M$165.7M$200K$3.8M10-Q 2026-10-28
Q2 2026
2026-06-30
$700K-$50.4M-$52.6M$174.9MNo debt tags$5.0M10-Q 2026-07-16
Q1 2026
2026-03-31
$900K-$47.6M-$49.1M$229.2MNo debt tags$5.8M10-Q 2026-04-30
Q4 2025
2025-12-31
$636K-$44.8M-$35.2M$194.2M$0$5.7M10-K 2026-03-26
Q3 2025
2025-09-30
$2.8M-$33.2M-$32.4M$69.8MNo debt tags$5.6M10-Q 2026-10-28
Q2 2025
2025-06-30
$1.5M-$41.9M-$33.9M$103.2MNo debt tags$3.9M10-Q 2026-07-16
Q1 2025
2025-03-31
$800K-$27.1M-$19.7M$13.0MNo debt tags$3.5M10-Q 2026-04-30
Q4 2024
2024-12-31
$511K-$23.0M-$12.3M$32.5MNo debt tags$4.2M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-07-27
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-10-28
Latest current report8-K2026-10-28
Latest proxyDEF 14A2026-05-11

Source: SEC EDGAR submissions feed, 578 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.4%
1 month+22.0%
3 months-21.5%
Year to date-42.5%
1 year-15.7%
From 52-week high-55.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
BBTXBambusa Therapeutics Inc.$15.98-0.68%$645.4M
FDMT4D Molecular Therapeutics Inc.$11.29-7.69%$636.5M
ATTOAttovia Therapeutics Inc.$14.72-2.68%$673.1M
CGEMCullinan Therapeutics Inc.$9.50-7.59%$616.7M
SRZNSurrozen Inc.$32.32+2.25%$616.1M
SLDBSolid Biosciences Inc.$6.48-5.26%$723.2M
SANASana Biotechnology Inc.$1.88-6.93%$563.3M
IAMIambic Therapeutics Inc.$11.85-9.54%$561.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier